FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782011123> ?p ?o ?g. }

• W2782011123 endingPage "229" @default.
• W2782011123 startingPage "229" @default.
• W2782011123 abstract "The associations between cardiovascular disease (CVD) and inhaled long-acting β2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) are greatly debated. Pivotal and relevant randomized clinical trials included prior LABA or LAMA users and excluded patients with baseline CVD; therefore, cardiovascular events arising from first-time LABA or LAMA use, if any, could not be observed. There is an urgent need to examine whether new use of and duration since initiating LABAs and LAMAs could act as important determinants of cardiovascular events.To investigate risk of CVD associated with LABAs and LAMAs, focusing on the initiation and duration of LABA and LAMA therapies.This nested case-control study included 284 220 LABA-LAMA-naïve patients with COPD at least 40 years old (mean age, 71.4 years; 68.9% men), retrieved from the Taiwan National Health Insurance Research Database for health care claims from 2007 to 2011.LABA or LAMA use was measured in the year preceding the event or index date, stratified by duration since initiation of LABA or LAMA treatment, new and prevalent users, concomitant COPD medications, and individual agents.Cases with inpatient or emergency care visits for coronary artery disease, heart failure, ischemic stroke, or arrhythmia were identified and individually matched to 4 randomly selected controls. Conditional logistic regressions were performed to estimate odds ratios of CVD from LABA and LAMA treatment.During a mean follow-up of 2.0 years, 37 719 patients with CVD (mean age, 75.6 years; 71.6% men) and 146 139 matched controls (mean age, 75.2 years; 70.1% men) were identified. New LABA and LAMA use in COPD was associated with a 1.50-fold (95% CI, 1.35-1.67; P < .001) and a 1.52-fold (95% CI, 1.28-1.80; P < .001) increased cardiovascular risk within 30 days of initiation, respectively, whereas the risk was absent, or even reduced with prevalent use. Individual LABA agents, LAMA dosage forms, and concomitant COPD regimens did not differ in the CVD risks. The risk persisted in an alternative case-crossover study and remained across subgroups without CVD history or prior exacerbations.New initiation of LABAs or LAMAs in patients with COPD is associated with an approximate 1.5-fold increased severe cardiovascular risk, irrespective of prior CVD status and history of exacerbations." @default.
• W2782011123 created "2018-01-12" @default.
• W2782011123 creator A5019321711 @default.
• W2782011123 creator A5020366111 @default.
• W2782011123 creator A5032383836 @default.
• W2782011123 creator A5047664457 @default.
• W2782011123 creator A5052801069 @default.
• W2782011123 creator A5071294927 @default.
• W2782011123 creator A5079854584 @default.
• W2782011123 date "2018-02-01" @default.
• W2782011123 modified "2023-10-15" @default.
• W2782011123 title "Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease" @default.
• W2782011123 cites W1593428479 @default.
• W2782011123 cites W1821044976 @default.
• W2782011123 cites W1970867142 @default.
• W2782011123 cites W1992457066 @default.
• W2782011123 cites W1997977823 @default.
• W2782011123 cites W2014032502 @default.
• W2782011123 cites W2016274438 @default.
• W2782011123 cites W2016513153 @default.
• W2782011123 cites W2022952350 @default.
• W2782011123 cites W2032171019 @default.
• W2782011123 cites W2046206328 @default.
• W2782011123 cites W2054329313 @default.
• W2782011123 cites W2072038990 @default.
• W2782011123 cites W2082081076 @default.
• W2782011123 cites W2083557491 @default.
• W2782011123 cites W2090866271 @default.
• W2782011123 cites W2097149135 @default.
• W2782011123 cites W2097281517 @default.
• W2782011123 cites W2109186037 @default.
• W2782011123 cites W2110818436 @default.
• W2782011123 cites W2112904335 @default.
• W2782011123 cites W2113079553 @default.
• W2782011123 cites W2127951128 @default.
• W2782011123 cites W2134122420 @default.
• W2782011123 cites W2135917172 @default.
• W2782011123 cites W2139397407 @default.
• W2782011123 cites W2141034778 @default.
• W2782011123 cites W2142724633 @default.
• W2782011123 cites W2149199480 @default.
• W2782011123 cites W2166538093 @default.
• W2782011123 cites W2174659623 @default.
• W2782011123 cites W2293877492 @default.
• W2782011123 cites W2341453907 @default.
• W2782011123 cites W2344148139 @default.
• W2782011123 cites W2570608423 @default.
• W2782011123 cites W2601378666 @default.
• W2782011123 doi "https://doi.org/10.1001/jamainternmed.2017.7720" @default.
• W2782011123 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5838614" @default.
• W2782011123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29297057" @default.
• W2782011123 hasPublicationYear "2018" @default.
• W2782011123 type Work @default.
• W2782011123 sameAs 2782011123 @default.
• W2782011123 citedByCount "95" @default.
• W2782011123 countsByYear W27820111232018 @default.
• W2782011123 countsByYear W27820111232019 @default.
• W2782011123 countsByYear W27820111232020 @default.
• W2782011123 countsByYear W27820111232021 @default.
• W2782011123 countsByYear W27820111232022 @default.
• W2782011123 countsByYear W27820111232023 @default.
• W2782011123 crossrefType "journal-article" @default.
• W2782011123 hasAuthorship W2782011123A5019321711 @default.
• W2782011123 hasAuthorship W2782011123A5020366111 @default.
• W2782011123 hasAuthorship W2782011123A5032383836 @default.
• W2782011123 hasAuthorship W2782011123A5047664457 @default.
• W2782011123 hasAuthorship W2782011123A5052801069 @default.
• W2782011123 hasAuthorship W2782011123A5071294927 @default.
• W2782011123 hasAuthorship W2782011123A5079854584 @default.
• W2782011123 hasBestOaLocation W27820111231 @default.
• W2782011123 hasConcept C126322002 @default.
• W2782011123 hasConcept C156957248 @default.
• W2782011123 hasConcept C164705383 @default.
• W2782011123 hasConcept C168563851 @default.
• W2782011123 hasConcept C1862650 @default.
• W2782011123 hasConcept C194828623 @default.
• W2782011123 hasConcept C2776780178 @default.
• W2782011123 hasConcept C2778198053 @default.
• W2782011123 hasConcept C2779134260 @default.
• W2782011123 hasConcept C2779384505 @default.
• W2782011123 hasConcept C2780911369 @default.
• W2782011123 hasConcept C71924100 @default.
• W2782011123 hasConceptScore W2782011123C126322002 @default.
• W2782011123 hasConceptScore W2782011123C156957248 @default.
• W2782011123 hasConceptScore W2782011123C164705383 @default.
• W2782011123 hasConceptScore W2782011123C168563851 @default.
• W2782011123 hasConceptScore W2782011123C1862650 @default.
• W2782011123 hasConceptScore W2782011123C194828623 @default.
• W2782011123 hasConceptScore W2782011123C2776780178 @default.
• W2782011123 hasConceptScore W2782011123C2778198053 @default.
• W2782011123 hasConceptScore W2782011123C2779134260 @default.
• W2782011123 hasConceptScore W2782011123C2779384505 @default.
• W2782011123 hasConceptScore W2782011123C2780911369 @default.
• W2782011123 hasConceptScore W2782011123C71924100 @default.
• W2782011123 hasIssue "2" @default.
• W2782011123 hasLocation W27820111231 @default.
• W2782011123 hasLocation W27820111232 @default.
• W2782011123 hasLocation W27820111233 @default.

• next